SAN DIEGO, Nov. 27, 2017 /PRNewswire/ -- Immix Biopharma, Inc. today announced it has added Mesa Verde Venture Partners to its investor syndicate. Mesa Verde joins a group of investors that includes Takeda Ventures, Inc., MP Healthcare Venture Management, and BioMed Ventures. Immix Biopharma also announced it has received Institutional Review Board (IRB) approval to enroll patients in the United States for its Phase 1b/2a clinical trial of IMX-110 for the treatment of advanced solid tumors. IMX-110 is a highly selective inhibitor of CXCR4, a chemokine receptor that plays a key role in tumor growth, metastasis, and resistance to therapy. The study will evaluate the safety and efficacy of IMX-110 in patients with advanced solid tumors, including those that have failed prior therapies. "We are pleased to welcome Mesa Verde to our investor syndicate," said Ilya Rachman, MD, PhD, CEO of Immix Biopharma. "Their investment will help us to advance the development of IMX-110 and other promising cancer therapies." Dr. Rachman added, "We are also excited to have received IRB approval to enroll patients in our Phase 1b/2a clinical trial. This is a significant milestone for Immix Biopharma, and we look forward to initiating the study in the near future." "We are impressed with the Immix Biopharma team and the potential of IMX-110 to address a significant unmet medical need in cancer," said Alan Marks, Managing Director of Mesa Verde Venture Partners. "We are pleased to support the company as it advances this important clinical program." About Immix Biopharma Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of cancer. The company's lead product candidate, IMX-110, is a highly selective inhibitor of CXCR4, a chemokine receptor that plays a key role in tumor growth, metastasis, and resistance to therapy. IMX-110 is currently being evaluated in a Phase 1b/2a clinical trial for the treatment of advanced solid tumors. Immix Biopharma is headquartered in San Diego, California. About Mesa Verde Venture Partners Mesa Verde Venture Partners is a venture capital firm that invests in early-stage life sciences companies. The firm focuses on investments in companies that are developing innovative therapies for the treatment of cancer, infectious diseases, and other serious medical conditions. Mesa Verde Venture Partners is based in San Diego, California.